Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 228-235, May 2007

The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer☆

  • Mark L. Gonzalgo, M.D., Ph.D.

      Affiliations

    • Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    • ,
  • Ram H. Datar, Ph.D.

      Affiliations

    • Department of Pathology, USC–Keck School of Medicine, Los Angeles, CA 90033, USA
    • ,
  • Mark P. Schoenberg, M.D.

      Affiliations

    • Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    • ,
  • Richard J. Cote, M.D.

      Affiliations

    • Departments of Pathology and Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-323-442-1156; fax: +1-323-442-1154.

Received 6 February 2006; received in revised form 20 June 2006; accepted 14 July 2006.

Abstract 

Alterations in global levels and regional patterns of deoxyribonucleic acid methylation are among the earliest and most common events known to occur in human cancer. The mutational and epigenetic effects of this covalent deoxyribonucleic acid modification to the development of bladder cancer are well recognized. The contribution of aberrant methylation to mutational hot spots located within genes, transcriptional silencing, and chromosomal instability is reviewed in the context of its relevance to bladder carcinogenesis. Understanding how such processes evolve during the progression of bladder cancer is essential for using these molecular changes in the clinical setting. The recent development of sensitive and specific techniques for quantifying methylation changes in urine specimens and bodily fluids underscores the potential use of this molecular marker for early detection and surveillance of bladder cancer. Further refinement of these molecular biological techniques holds much promise for the use of methylation markers for bladder cancer diagnosis, risk stratification, and disease prognostication.

Keywords: DNA methylation, Bladder cancer, Diagnosis, Prognosis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ The Molecular and Cellular Pathways of Bladder Cancer Progression Grant (No. NCI CA 70903), the Cancer Center Core Grant (NCI CA 14089), and the Bladder Cancer Program Project Grant (No. PO1 CA 86871) provided research support for R.H.D. and R.J.C.

PII: S1078-1439(06)00242-0

doi:10.1016/j.urolonc.2006.07.020

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 228-235, May 2007

Article Tools

* Image Usage & Resolution